Quviviq (Daridorexant HCl) Patent Expiration, LOE Window & CMS Spending

Quviviq (Daridorexant HCl) by Idorsia: FDA Orange Book core substance LOE 2034-12-02, 0 AB generics, $35.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIdorsia
FDA Application & PathwayN214985 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-12-02
Last Listed Patent or Exclusivity Date2034-12-02
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$35.5M
2024 Medicare Part D Spend$24.4M
2024 Medicaid Spend$11.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel